Waddell & Reed Science & Tech AUNSCX

Morningstar Rating

Fund Research and Analysis

by Greg Brown

Waddell & Reed Advisors Science & Technology has struggled to keep up with peers lately, but its long-term merits are sound.

The good news is that this fund is up more than 26% year to date through August 5, 2009. The bad news, however, is Read more

Kudos

By keeping a good chunk of the portfolio outside of the tech sector and occasionally holding large amounts of cash, this fund has been one of the least volatile tech offerings.

This fund's health-care stake helped shield it from shattering losses during the bear market.

Low turnover. Read more

Risks

The fund's moves into cash and its focus on nontech names won't appeal to style purists or those who want to make their own asset-allocation decisions.

It has tended to lag in tech-stock rallies. Read more

Strategy

Manager Zachary Shafran tends to make sizable shifts between tech, health care, and cash. He invests in companies that he thinks can increase revenue and earnings by at least 20% per year. Like his predecessors, Read more

Management

Zachary Shafran came aboard here in February 2001 after short stints at both Waddell & Reed Advisors New Concepts UNECX and W&R (now Ivy) Mid Cap Growth WMGYX. Before that, he was a longtime analyst with the firm, covering both the technology Read more

Inside Scoop

Big health-care and cash stakes have perked up this fund's returns when other tech funds have suffered. Its long-term record is strong, though. Read more

First Name

Last Name

Email Address

Zip Code

Create Password

Verify Password

(6-15 characters; case sensitive)

What is your occupation or job title?

Select...

Your registration indicates agreement to the terms of use.

Dodge & Cox: Health Care Now More Attractive
Watch more